Gilitinib is an oral inhibitor of receptor tyrosine kinases (RTKs), FMS related tyrosine kinases 3 (FLT3, STK1 or FLK2), AXL (UFO or JTK11), and non pigmented lymphoma kinases (ALK or CD246), with potential anti-tumor activity. Gilitinib can bind and inhibit wild-type and mutant FLT3, AXL, and ALK. This may lead to inhibition of signal transduction pathways mediated by FLT3, AXL, and ALK, and reduce tumor cell proliferation in cancer cell types that overexpress these RTKs. FLT3, AXL, and ALK are overexpressed or mutated in various types of cancer cells, playing a crucial role in the growth and survival of tumor cells.